We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Maxcyte Inc | LSE:MXCT | London | Ordinary Share | COM STK USD0.01 (DI) |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 345.00 | 340.00 | 350.00 | 345.00 | 345.00 | 345.00 | 16,000 | 07:43:32 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Biological Pds,ex Diagnstics | 44.26M | -23.57M | -0.2277 | -18.97 | 447.14M |
Date | Subject | Author | Discuss |
---|---|---|---|
04/2/2021 12:12 | Fantastic chart of growth in number of partnerships. And we know its only going to get better... "Coming into 2021 our strategic partnership pipeline is the largest we have seen" | someuwin | |
04/2/2021 11:29 | Thanks AdamB - Yes of course AIM is very lightly regulated - good point. Perhaps when MXCT listed on AIM they were unable to make NAS listing criteria at that time as you infer. It's going to be an interesting few months. This stock is not that widely followed over here - yet. So there is plenty of room for improvement! Good luck and thanks | gustocomeon | |
04/2/2021 11:14 | Gustocomeon Nadsaq's listing criteria are pretty stringent - its not a lightly regulated market - so they could list on AIM far earlier. I ran a set of comps for Mxct a week or two ago and the median ev/sales multiple was 28.8x! And thats the median...not high end! | adamb1978 | |
04/2/2021 11:08 | MXCT behaving very well. I was always intrigued as to why a US co would first list on AIM, and then later list on NASDAQ where valuations appear to be more generous than over here. Does anyone have any thoughts on that? And in view of an upcoming listing on NASDAQ who might be MXCT's peers for comparison purposes. They appear the a bit of a one off... DYOR etc I am a holder. | gustocomeon | |
04/2/2021 09:45 | "Expect to report accelerating revenue growth in 2021 ahead of market expectations driven by: - Progress of our existing strategic partners into and through the clinic with their lead programs; potential shift of pre-clinical programs into clinic - Addition of new customers and signing on new strategic partnerships - Coming into 2021 our strategic partnership pipeline is the largest we have seen" | someuwin | |
04/2/2021 09:40 | It's interesting that the fund raise would have been enough for trials on the CARMA product. It really shows the value now assigned to the core proposition, it's all become much more viable since the CX0001 outcome in December. Without doubt this fund raise was for US investors and liquidity in the stock. If you are querying the need for the capital, there is a further point of what are they planning on doing with a US placement that will probably be an absolute minimum of $1bn valuation. The $1bn excludes ANY progress in partner clinical trials and the likely sizable cash injection due from the CARMA out license (which no one seems to be referencing). As always there are downside risks, and this new liquidity could be used to keep the price sensible to support a US listing, with the UK as illiquid as it is, you can see the impact just us have on moving the price (and spread). Finally re the point on the takeover, well that really shows the value doesnt it? If CX0001 alone is $50m a year in royalities and MXCT as a whole is valued at £600m, well then it's a no brainer as a target (barring any change of control clauses in agreements, which could make sense as MXCT supply most of the co's in the sector). Enjoy the 14:00 show when the US comes online. | 2theduke | |
04/2/2021 09:38 | Amazing business model. License payments. Equipment sales. Recurring lease payments. Consumables payments. Milestone payments. Consultation payments. Plus, the holy grail of future royalties on successful product launches from their multiple big pharma partners. | someuwin | |
04/2/2021 09:24 | I think the money raised is just a bridge to raise investor awareness and appetite. Its only a small $ amount which has been raised and I'd imagine these investors will be looking for a large value holding, and are therefore going to be buyers post-Nasdaq listing. The balance sheet strength will also show that the company has the firepower to be able to accelerate growth once on Nasdaq, and therefore draw in more investors | adamb1978 | |
04/2/2021 09:19 | Perhaps they raised the money to strengthen shareholder base so they can keep would be acquirers at bay | nimbo1 | |
04/2/2021 09:17 | They're going to go crazy for this stock when it lists on NASDAQ later this year. | someuwin | |
04/2/2021 08:47 | N1 - from memory you compared it to a fridge maker and I compared your fridge maker to AO, who are more a fridge retailer to be fair, but your linkage seemed more tenuous. | trident5 | |
04/2/2021 08:44 | Amazing potential future royalties on success with any of these growing number of partner clinical trials... | someuwin | |
04/2/2021 08:41 | I see trident has been popping up and I can imagine the nature of his posts. Major case of sour grapes/fomo I imagine. I filtered him a couple of years ago from another thread. | assagai | |
04/2/2021 08:40 | A few double digit trades coming through - looks like a "Popular Investor/guru" has taken this to his/her "copy trades". Though not hugely mainstream as yet, the sheer volumes that these hordes of copy traders can trigger can be astounding. Not to be underestimated. Not completely dissimilar in structure to the GME saga...in some ways. Edit: I think we'll close £8+ today of the above pans out ! | multibagger | |
04/2/2021 08:22 | Great to see the share price ascending - validating what many of us thought would happen ! Time to nuke the Trident I think from responses on this board - I nuked/filtered a long time ago to save myself the drivel. | multibagger | |
04/2/2021 08:17 | I could go back and highlight plenty of remarks about 'ramping' when the price was closer to £4.50 and I said it could be a £1 bil co. You compared it to AO World FFS. Anyway no need to clog the board with this. Congrats all holders and GL - this has flown now, time to sit back and see where insti's want to value it - D1 investment puts it on the radar of all major US healthcare investors...they have a big following in the US. | nimbo1 | |
04/2/2021 08:13 | What's snarky about highlighting the director sale and then asking a question about it? | trident5 | |
04/2/2021 08:09 | Congrats trident - why the stream of snarky posts then? Doesn't befit a long term holder. Its getting on for a 6x for me from my initial 1.15 buy. My average is much higher though as have averaged up with volume...but who's counting up here! | nimbo1 | |
04/2/2021 08:02 | Good start. | someuwin | |
04/2/2021 08:01 | 74 - it was a question - so not wrong. N1 - price up 3x since I bought, fella. | trident5 | |
04/2/2021 07:52 | trident is intellectually challenged - price up about 60% since he started posting...I say long may it continue. 5 mm's at £7... | nimbo1 | |
04/2/2021 07:47 | Yes... you feeling a bit stupid yet Trident? You’ve been completely & utterly wrong on this one, a tragic comedy! | 74tom | |
04/2/2021 07:42 | When they issued their RNS after markets closed last night it said the directors were going to exercise their options with an intention to sell the shares. This morning before markets opened the RNS said they have been sold. Are they able to sell these off the market? | trident5 | |
03/2/2021 22:54 | Spot on I think. There dont appear to be any negatives in selling by insiders if you study the subtleties! Be interesting to see if we reset to £7 at the off in the morning.... As a starting point!... | assagai |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions